BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24698864)

  • 21. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rifaximin for the treatment of hepatic encephalopathy.
    Mantry PS; Munsaf S
    Transplant Proc; 2010 Dec; 42(10):4543-7. PubMed ID: 21168733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
    Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
    J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving treatments for hepatic encephalopathy.
    Gastroenterol Nurs; 2012; 35(4):291-2. PubMed ID: 22847290
    [No Abstract]   [Full Text] [Related]  

  • 25. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
    Rahimi RS; Brown KA; Flamm SL; Brown RS
    Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.
    Hudson M; Schuchmann M
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):434-450. PubMed ID: 30444745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevention and treatment of hepatic encephalopathy].
    Sivolap YP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rifaximin treatment in hepatic encephalopathy.
    Bass NM; Mullen KD; Sanyal A; Poordad F; Neff G; Leevy CB; Sigal S; Sheikh MY; Beavers K; Frederick T; Teperman L; Hillebrand D; Huang S; Merchant K; Shaw A; Bortey E; Forbes WP
    N Engl J Med; 2010 Mar; 362(12):1071-81. PubMed ID: 20335583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can we ignore minimal hepatic encephalopathy any longer?
    Qadri AM; Ogunwale BO; Mullen KD
    Hepatology; 2007 Mar; 45(3):547-8. PubMed ID: 17326151
    [No Abstract]   [Full Text] [Related]  

  • 30. Diagnostic Performance of the ICD-10 Code K76.82 for Hepatic Encephalopathy in Patients With Cirrhosis.
    Ozturk NB; Jamil LH; Tapper EB
    Am J Gastroenterol; 2024 Feb; 119(2):364-366. PubMed ID: 37830544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rifaximin therapy in minimal hepatic encephalopathy cirrhotics.
    Zullo A; Hassan C; Lorenzetti R
    Am J Gastroenterol; 2011 Nov; 106(11):2041; author reply 2041-2. PubMed ID: 22056578
    [No Abstract]   [Full Text] [Related]  

  • 32. Gut flora and hepatic encephalopathy in patients with cirrhosis.
    Riordan SM; Williams R
    N Engl J Med; 2010 Mar; 362(12):1140-2. PubMed ID: 20335591
    [No Abstract]   [Full Text] [Related]  

  • 33. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis.
    Bajaj JS; Pinkerton SD; Sanyal AJ; Heuman DM
    Hepatology; 2012 Apr; 55(4):1164-71. PubMed ID: 22135042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment.
    Fritz MK; Mangino AA; Hunt TV; Pitcock CT; Dugan AJ; Karri K; Yarra P
    Ann Pharmacother; 2023 Aug; 57(8):899-906. PubMed ID: 36367093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rifaximin and nonabsorbable disaccharides for hepatic encephalopathy.
    Guslandi M; Cella A
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):376. PubMed ID: 20134260
    [No Abstract]   [Full Text] [Related]  

  • 37. Mechanisms, diagnosis and management of hepatic encephalopathy.
    Prakash R; Mullen KD
    Nat Rev Gastroenterol Hepatol; 2010 Sep; 7(9):515-25. PubMed ID: 20703237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug therapy: rifaximin.
    Bajaj JS; Riggio O
    Hepatology; 2010 Oct; 52(4):1484-8. PubMed ID: 20814894
    [No Abstract]   [Full Text] [Related]  

  • 39. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rifaximin for the treatment of hepatic encephalopathy.
    Mullen K; Prakash R
    Expert Rev Gastroenterol Hepatol; 2010 Dec; 4(6):665-77. PubMed ID: 21108586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.